Heron Therapeutics Inc (HRTX) concluded trading on Wednesday at a closing price of $1.71, with 4.67 million shares of worth about $7.99 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -12.31% during that period and on Wednesday the price saw a gain of about 1.79%. Currently the company’s common shares owned by public are about 151.70M shares, out of which, 150.77M shares are available for trading.
Stock saw a price change of 1.18% in past 5 days and over the past one month there was a price change of -5.52%. Year-to-date (YTD), HRTX shares are showing a performance of 11.76% which decreased to -34.23% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.04 but also hit the highest price of $3.93 during that period. The average intraday trading volume for Heron Therapeutics Inc shares is 2.93 million. The stock is currently trading -0.61% below its 20-day simple moving average (SMA20), while that difference is up 2.93% for SMA50 and it goes to -21.77% lower than SMA200.
Heron Therapeutics Inc (NASDAQ: HRTX) currently have 151.70M outstanding shares and institutions hold larger chunk of about 75.77% of that.
The stock has a current market capitalization of $260.08M and its 3Y-monthly beta is at 1.64. It has posted earnings per share of -$0.18 in the same period. It has Quick Ratio of 1.74. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for HRTX, volatility over the week remained 6.17% while standing at 6.28% over the month.
Stock’s fiscal year EPS is expected to rise by 83.94% while it is estimated to increase by 52.61% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Rodman & Renshaw on June 13, 2024 offering a Buy rating for the stock and assigned a target price of $7 to it. Coverage by CapitalOne stated Heron Therapeutics Inc (HRTX) stock as an Overweight in their note to investors on April 23, 2024, suggesting a price target of $6 for the stock. On March 13, 2024, Needham Reiterated their recommendations, while on May 27, 2020, Guggenheim Initiated their ratings for the stock with a price target of $24. Stock get a Buy rating from Needham on February 20, 2020.
